I just wanted to highlight the following observation;
'Off Label Drug Use may highlight conditions which warrant supplementary clinical trials'.
Off Label use could be cost effective in opening the doorway to study the effect of Trofinetide on a range of neurodevelopmental and neurodegenerative disorders.
Reasons for consideration, page-99
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.08 |
Change
-1.010(5.91%) |
Mkt cap ! $2.079B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $21.09M | 1.339M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 437 | $16.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.09 | 101 | 5 |
View Market Depth
| Last trade - 15.00pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |